

Delawareans Agree: It's Time to Ensure 340B Works for Patients as Intended

National Poll Demonstrates Strong Support for Patient-Centered Reform of the 340B Drug Pricing Program



The 340B Drug Pricing Program was created to help low-income and uninsured patients access their life-saving medications and care. Unfortunately, some 340B hospitals, the pharmacies they contract with, and pharmacy benefit managers (PBMs) have manipulated the program into a massive profit-generating scheme by failing to pass drug discount savings onto patients.

Polled Delawareans Agree: 340B Should Benefit Patients, Not Hospital & Middlemen Profits

Direct Patient Benefit



77% of surveyed adults in Delaware agree that hospitals receiving 340B discounts should be required to pass those savings on to low-income and vulnerable patients.

More Transparency



77% of surveyed adults in Delaware support increasing transparency by allowing for audits on how hospitals and pharmacies are using 340B.

Debt Collection



76% of surveyed adults in Delaware are concerned that many 340B hospitals use aggressive debt collection practices against patients who cannot afford care.



"340B has veered wildly off course to the detriment of patients. Today, the program has morphed into a financial bonanza for "non-profit" hospitals and the nation's biggest chain retail pharmacies while patients in desperate financial need don't get the benefits of 340B drug discounts... Congress must act now to restore 340B to its original mission—ensuring it helps the low-income and vulnerable patients it was designed to serve."

- Sally Greenberg, CEO, National Consumers League (NCL)

Delaware Lawmakers: Reform the 340B Program to Protect Patients

Congress must advance comprehensive federal reforms to the 340B Drug Pricing Program to ensure it benefits patients in need, not hospitals and health industry middlemen.



nationalconsumersleague



nationalconsumersleague



ncl-tweets





